HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, announced it will host a conference call on May 13, 2026, at 4:30 p.m. Eastern time to discuss first-quarter results ended March 31, 2026, and provide updates on key growth initiatives. These include its limited commercial launch for arrhythmia assessment, extended-wear patch development, heart attack detection and AI programs.
The company is developing the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility, potentially redefining the future of cardiac health management.
HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to technology enablement. The upcoming call will likely provide insight into the progress of the limited commercial launch and the development of an extended-wear patch, which could expand the company's market reach.
The importance of this announcement lies in the potential impact on cardiac care. HeartBeam’s technology aims to enable remote monitoring and detection of arrhythmias and heart attacks, which could reduce hospital visits and improve patient outcomes. For investors, the updates on commercial launch and AI programs will be critical in assessing the company's growth trajectory and market adoption. For more information, visit the company's newsroom at https://nnw.fm/BEAT.
The conference call will also address the company's first-quarter financial performance, providing a baseline for evaluating its operational progress. As HeartBeam moves from development to commercialization, the limited launch for arrhythmia assessment represents a key milestone. The extended-wear patch and AI programs could further differentiate the company in the competitive cardiac monitoring market.
HeartBeam’s cleared indications for use are available at https://www.heartbeam.com/indications. The company’s technology has the potential to impact patients by enabling earlier detection of cardiac issues, which could lead to timely interventions and better health outcomes. For the healthcare industry, the shift toward remote monitoring and AI-driven diagnostics could reduce costs and improve efficiency.
The full press release is available at https://ibn.fm/yN939. Investors and industry observers will be watching the May 13 call for signs of commercial traction and technological advancements that could shape the future of cardiac care.
